Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.

J Immunother Cancer · 2022 · PMC9114963 · PMID 35577503

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

ICB-experienced NSCLC and MEL patients showed a trend for higher CSF1R+and CD163+TAM infiltrates compared with ICB-naïve UBC patients at baseline ( figure 4A, B ).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The overall CD8 +T cell vs CD163 +TAM ratio was higher in the non-PD group at baseline (23.6% in the PD vs 70.5% in the non-PD) but this did not reach statistical significance ( online supplemental figure 2c ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.